Advancing precision medicine:the transformative role of artificial intelligence in immunogenomics,radiomics,and pathomics for biomarker discovery and immunotherapy optimization  

作　　者：Luchen Chang Jiamei Liu Jialin Zhu Shuyue Guo Yao Wang Zhiwei Zhou Xi Wei 

机构地区：[1]Department of Diagnostic and Therapeutic Ultrasonography,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin’s Clinical Research Center for Cancer,Tianjin 300060,China [2]Departments of Biochemistry and Radiation Oncology,UT Southwestern Medical Center,Dallas 75390,USA

出　　处：《Cancer Biology & Medicine》2025年第1期33-47,共15页癌症生物学与医学(英文版)

基　　金：supported by grants from the National Natural Science Foundation of China(Grant No.82272008);The Science&Technology Development Fund of Tianjin Education Commission for Higher Education(Grant No.2021KJ194);Tianjin Key Medical Discipline(Specialty)Construction Project(Grant No.TJYXZDXK-009A).

摘　　要：Artificial intelligence(AI)is significantly advancing precision medicine,particularly in the fields of immunogenomics,radiomics,and pathomics.In immunogenomics,AI can process vast amounts of genomic and multi-omic data to identify biomarkers associated with immunotherapy responses and disease prognosis,thus providing strong support for personalized treatments.In radiomics,AI can analyze high-dimensional features from computed tomography(CT),magnetic resonance imaging(MRI),and positron emission tomography/computed tomography(PET/CT)images to discover imaging biomarkers associated with tumor heterogeneity,treatment response,and disease progression,thereby enabling non-invasive,real-time assessments for personalized therapy.Pathomics leverages AI for deep analysis of digital pathology images,and can uncover subtle changes in tissue microenvironments,cellular characteristics,and morphological features,and offer unique insights into immunotherapy response prediction and biomarker discovery.These AI-driven technologies not only enhance the speed,accuracy,and robustness of biomarker discovery but also significantly improve the precision,personalization,and effectiveness of clinical treatments,and are driving a shift from empirical to precision medicine.Despite challenges such as data quality,model interpretability,integration of multi-modal data,and privacy protection,the ongoing advancements in AI,coupled with interdisciplinary collaboration,are poised to further enhance AI’s roles in biomarker discovery and immunotherapy response prediction.These improvements are expected to lead to more accurate,personalized treatment strategies and ultimately better patient outcomes,marking a significant step forward in the evolution of precision medicine.

关 键 词：Artificial intelligence tumor immune microenvironment GENOMICS TRANSCRIPTOMICS radiomics pathomics 

分 类 号：R319[医药卫生—基础医学] TP18[自动化与计算机技术—控制理论与控制工程]